PIN40 COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION AMONG INFANTS IN RUSSIA: ECONOMIC EVALUATION OF THE PNEUMOCOCCAL 7-VALENT CONJUGATE VACCINE  by Omelyanovsky, VV et al.
13th Euro Abstracts A437
to reduce 12.8 to 39.0 deaths (PCV13) and 12.4 to 37.3 deaths (PHiD-CV) per 
100,000 vaccinated children. The model predicts that PHiD-CV will prevent 93 to 
494 additional Myringotomies and 651 to 8,314 additional AOM cases per 100,000 
vaccinated children, when compared with PCV13. Medical costs averted are estimated 
similar for ID and CAP. The model predicts that PHiD-CV will prevent 48 to 116% 
more AOM associated costs to the health care system over lifetime than PCV13. In 
the scenarios analyzed, both vaccines are cost-effective but PHiD-CV generates more 
QALYs gains (range 0.04%–14.5%) and is cost saving (range 1.88–12.54%) com-
pared to PCV13. CONCLUSIONS: The model shows both vaccines would signiﬁ -
cantly reduce the clinical & economic burden of Pneumococcal disease and are 
cost-effective for Latin American countries. Nevertheless, due to its greater impact on 
AOM-related cases and costs, PHiD-CV would generate more QALY gains and is 
cost-saving to the health care system compared to PCV13.
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OBJECTIVES: To estimate the cost-effectiveness of the recommended US pediatric 
vaccination schedule from a public health perspective. METHODS: An Excel-based 
cost-effectiveness calculator was constructed for the current pediatric vaccine schedule 
including: diphtheria, tetanus, and pertussis (DTaP), measles, mumps, and rubella 
(MMR), polio, hepatitis A, hepatitis B, haemophilus inﬂ uenza B (Hib), varicella, 
pneumococcal, adolescent meningococcal, inﬂ uenza, human papillomavirus (HPV) 
and rotavirus vaccines. Estimates of the incremental direct medical costs and quality-
adjusted life-years (QALYs) for vaccination versus no vaccination were obtained from 
published literature. Where estimates were not available, a decision tree was con-
structed to model QALYs gained per vaccinated child. The tree includes branches for 
disease incidence pre- and post-vaccine introduction, case-fatality, and permanent, 
serious sequelae. 2008–2009 vaccination coverage and 2009 prices were used to 
estimate vaccine costs. Estimates of lifetime costs and QALYs per vaccinated child, 
discounted at 3% annually, were applied to a US birth cohort, assuming direct effects 
only. Costs are expressed in 2009 US$. Incremental costs and QALYs for individual 
vaccines and the whole schedule were evaluated. The model assessed schedule comple-
tion with single disease vaccines as well as completion with two different pentavalent 
combination vaccines (DTaP, polio, Hib or DTap, polio, hepatitis B) plus single 
disease vaccines. RESULTS: Regardless of how the current pediatric vaccine schedule 
is completed, annual estimated cost savings range between $13.8 billion to $14.3 
billion. DTaP, MMR, polio, Hib and HPV are cost-saving, as are both pentavalent 
vaccines. Other single-disease vaccines add cost but contribute to a total of 1.4M 
QALYs gained per year. CONCLUSIONS: The current US pediatric vaccine schedule 
is estimated to be cost-saving and to provide substantial beneﬁ ts in quality-adjusted 
survival. Use of combination vaccines increases the savings. Neither herd immunity 
nor indirect costs were considered in the model; their inclusion likely would increase 
the estimated cost savings.
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OBJECTIVES: To build a Markov Model that is able to assess the cost-effectiveness 
of adding NAT to the HIV screening strategy at the Brazilian public health system. 
METHODS: A mathematical model was made of the transfusion chain from donors 
to recipients of blood in Brazil. The annual number of avoided HIV transmissions was 
estimated with the window-period incidence model. The natural history of the whole 
blood receptors is described by a Markov model. RESULTS: The incremental cost-
effectiveness ratio—ICER of using NAT instead of ELISA concurrently to another 
ELISA in Brazilian public health system is R$666.493,56 per QALY. The Brazilian 
gross domestic product per capita is R$18.315,50. CONCLUSIONS: The Markov 
Model built is consistent and shows that, despite the narrower window period, at 
current costs, NAT is not cost-effective for HIV screening of donated blood in Brazil. 
Given that the NAT kit is already being produced in-house, the price per kit can be 
adjusted to achieve a better ICER.
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OBJECTIVES: Cost-effectiveness analysis of 4 dose (3 + 1) schedule of the conjugate 
pneumococcal 7-valent vaccine (PCV-7) in infants in the Russian Federation. 
METHODS: Costs associated with Streptococcus pneumoniae infection were calcu-
lated in a modeled cohort of children 0–5 years old with and without vaccination with 
PCV-7. Key parameters in the model included: number of children in the age of 0–5 
years in the country; incidence of diseases caused by S. pneumoniae; the data about 
efﬁ cacy of PVC-7. Costs of vaccination, medical care costs and economic losses of a 
society were taken into account from the societal point of view. Time horizon was 5 
years in the model. RESULTS: Expected cost of vaccination program is c0.469 million. 
Implementation of vaccination with PCV-7 will decrease direct medical costs of care 
for S. pneumoniae infection by c0.516 million. Societal economic losses will decrease 
by c0.975 million. Thus beneﬁ t amount of the PCV-7 vaccination program in a cohort 
of 0–5 years old children will be c1022 million. CONCLUSIONS: Vaccination with 
PCV-7 is an efﬁ cient program in Russia.
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OBJECTIVES: The impact of the HPV(6,11,16,18) vaccine to 12-year-old girls has 
been assessed in Germany by using a static model. However this kind of model cannot 
consider a change in HPV infection rate over time, as observed with high coverage 
rates. Further, this model does not adequately reﬂ ect the recommendation in Germany 
to vaccinate 12 to 17-year-old-girls. a transmission dynamic model was developed for 
the USA to include these features. Our objective was the adaptation of this model to 
Germany to precise the assessment of HPV-vaccination impact. METHODS: In a ﬁ rst 
step we assessed the transferability of the model structure to Germany. In a second 
step we checked input parameters for transferability and identiﬁ ed parameters for 
adaptation. For the identiﬁ ed parameters, we performed a comprehensive literature 
research, supplemented by expert opinions to determine German-speciﬁ c values. The 
model was manually calibrated to ﬁ t observed data in Germany. Calibration param-
eters were number of annual cases of genital warts and cervical cancer as well as 
deaths due to cervical cancer to reﬂ ect the entire time span of occurrence of HPV-
related diseases. RESULTS: The US model structure is also applicable to the German 
context. Components of the model that had to be adapted include demographics (e.g. 
mortality), screening participation, treatment and vaccination strategies, sexual behav-
iour, health utility and economic input parameters. In case no German-speciﬁ c data 
could be found, we used data from the UK and the US. Annual number of incidental 
genital warts was calibrated easily and ﬁ ts well with observed data. However, changes 
in a variety of parameters were necessary for calibration of cervical cancer cases and 
related deaths. CONCLUSIONS: After its successful adaptation, this transmission 
dynamic model can be used for a far more realistic estimation of the clinical and 
economic impact of HPV vaccination in the German context.
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BACKGROUND: Streptococcus pneumonia causes invasive diseases as meningitis and 
bacteremia and non-invasive diseases as pneumonia and acute otitis media (AOM), 
leading to high morbidity and mortality in infants and the elderly worldwide. 
OBJECTIVES: To evaluate the cost-effectiveness of universal infant vaccination with 
13-valent pneumococcal conjugate vaccine (PCV13) compared with PCV10 in 
Taiwan. METHODS: A Markov model was developed to evaluate the potential public 
health and economic impact of PCV13 versus PCV10 when used as routine vaccina-
tion of infants in Taiwan with 4 doses at 2, 4, 6, and 12–15 months of age over a 
10-year time horizon. We included both direct and potential indirect beneﬁ ts of the 
vaccine from societal perspective. Direct effectiveness of PCV13 and PCV10 is esti-
mated from clinical trial data while indirect effectiveness is estimated from U.S. surveil-
lance data. Epidemiology, serotype, medical, and non-medical cost are from Taiwan 
CDC report, and retrospective Taiwan-population-based insurance database. Other 
model parameters were captured by published sources, unpublished data, and assump-
tions made in consultation with clinical experts. Probabilistic sensitivity analyses was 
performed to test the robustness of model assumptions. RESULTS: At vaccination 
price (PCV13 cost used current PCV7 price of NT$3,200 (US$ 98) and PCV10 
NT$2,700 (US$ 83), our model predicts that, compared to PCV10, universal infant 
PCV13 vaccination would avoid 2,215 cases of IPD, approximately 12,473 and 
14,018 cases of hospitalized and non-hospitalized pneumonia, 246,578 cases of AOM; 
prevent 207 deaths from IPD and 85 deaths from hospitalized pneumonia; resulting 
in 4,596 life-years saved, and 3,359 QALYs gained. Comparing PCV13 to PCV10 
results in NT$ 187,462 (US$ 5,768) per life-year saved and cost of NT$ 253,307 (US$ 
7,794) per QALY gained from the societal perspective. CONCLUSIONS: Universal 
pediatric PCV13 vaccination in Taiwan is estimated to reduce the burden of pneumo-
coccal disease and expected to be cost-effective from the societal perspective compared 
with PCV10.
